Nabil et al. developed CD44-targeted hydrophobic drug (CFM-4.16)-loaded polymeric NPs to improve drug solubility, tumor accumulation, and anticancer efficacy against TNBC at in vitro and in vivo levels. The gene discussed is CD44; the disease is neoplasm.